How effective is PARP inhibitor therapy for triple-negative breast cancer?

Triple-negative breast cancer lacks three commonly measured receptors, so hormone-blocking treatment and some targeted options are not suitable for this subtype. PARP inhibitors target a repair vulnerability rather than those receptors. They may be considered when testing identifies an inherited or tumour-related change affecting DNA repair, depending on whether treatment is being given before surgery, after surgery or for advanced disease.

The result is one part of the decision. Your oncologist also reviews earlier chemotherapy, the extent of disease, blood counts, kidney function, other medicines and your preferences. A repair-related change can make treatment worth discussing, but it cannot predict an exact response for one person.

Ask whether inherited testing, tumour testing or both are needed, and discuss genetic counselling if an inherited result is possible. Follow the prescribed schedule and keep appointments for blood tests and scans. Tell your team about tiredness, nausea, infections, bruising, bleeding and all medicines or supplements so they can decide whether supportive care or a dose change is needed.

Seek prompt advice for fever, chills, unusual bleeding, extensive bruising, severe breathlessness, chest pain, repeated vomiting or weakness that stops normal activities. Contact emergency services for collapse or serious breathing difficulty. These symptoms can have several causes, including treatment effects, so timely assessment matters.

Ask which test result supports this treatment, what goal it has in your situation, and how response will be assessed. Ask about the expected treatment schedule, blood-test monitoring, common side effects, fertility or pregnancy considerations where relevant, and what alternatives exist if the medicine is not tolerated.